Case report

A 44 year-old lady with chronic renal disease and intractable ulcers: a case report

Thejeswi Pujar*1,3 and Irene M Spinello2,3

Address: 1Kern Medical Center, 1830 Flower Street, Bakersfield, California 93305, USA, 2David Geffen School of Medicine at UCLA, Los Angeles, California, USA and 3Critical Care and Pulmonary Services, Kern Medical Center, 1830 Flower Street, Bakersfield, California 93305, USA

Email: Thejeswi Pujar* - thejeswip@gmail.com; Irene M Spinello - spinelloi@kernmedctr.com
* Corresponding author

Abstract

Calciphylaxis is a rare but potentially fatal condition occurring in patients with end stage renal disease on dialysis. Due to interplay of various factors, disturbances occur in the metabolism of calcium and phosphate leading to calcification within the vessel walls. The net result is tissue ischemia and necrosis. Clinically this presents as painful non-healing skin ulcers, which contribute to significant morbidity and mortality due to septic progression of the lesion. In this case report, we highlight the rapidly progressive nature of this disease, its etiopathogenesis and the role of early diagnosis in preventing life-threatening complications.

Introduction

A 44-year-old Caucasian female with chronic renal failure receiving dialysis for the past one year presented to our hospital complaining of two weeks of diarrhea and worsening nausea. She was scheduled to receive dialysis treatments thrice weekly but had continuously missed her scheduled appointments. At the time of her initial presentation she had not been dialyzed for the past two weeks. Her past medical history was also significant for type 2 diabetes mellitus, hypertension, dyslipidemia, anemia of chronic disease and bronchial asthma. She had a history of cholecystectomy and cesarean section. There was a strong family history of hypertension, coronary artery disease and diabetes mellitus. She denied smoking, alcohol intake or use of recreational drugs. Her current medications included Vicodin, Actos, insulin and albuterol HFA. She had history of allergy to Penicillin.

Physical examination

On examination she was disabled with morbid obesity and in no apparent distress. There was no evidence of pallor, cyanosis or jaundice. Her vital signs revealed heart rate of 106/min, BP 140/78 mm of Hg, temperature 95.4°F, respiratory rate 18/min, and saturating at 99% on room air. She had a surgically implanted left subclavian dialysis catheter. HEENT exam revealed mild dehydration. Systemic examination was significant for mild epigastric tenderness without guarding or rigidity. There were areas of ecchymoses over inner thighs. Peripheral pulses were normal.
Laboratory tests
Laboratory investigations revealed potassium of 3.1 mg/dL, bicarbonate 22 mEq/L, BUN 74 mg/dL, creatinine 6.3 mg/dL, anion gap 20 mEq/L, phosphorous 7.2 mg/dL, serum calcium 9.1 mg/dL, magnesium 1.5 mg/dL, hemoglobin 10.5 g/dL, hematocrit 30%, serum iron 29 mcg/dL, TIBC 84 mcg/dL, normal amylase, lipase, thyroid function tests and liver function tests except albumin of 1.4 g/dL. EKG revealed sinus rhythm with RBBB. Chest radiograph was normal.

Hospital course
The patient was admitted for hemodialysis, correction of electrolyte imbalance and for evaluation of diarrhea. Patient was started on epoetin alfa for anemia, sevelamer hydrochloride (Renagel) for hyperphosphatemia and heparin for thromboprophylaxis. Over the next several days, the diarrhea resolved but patient developed worsening body aches and thigh pain. Blood test revealed leukocytosis at 19.7 × 10^3/mm^3 with neutrophilia at 13.7 × 10^3/ microL, hemoglobin of 7.9 g/dL, hematocrit 25.3%, without any evidence of bleeding. Stool tests were non-contributory. Blood cultures revealed methicillin sensitive staphylococcus aureus (MSSA) from the peripheral intravenous line as well as a surgically implanted long-term dialysis catheter (Ash-cath). The site of Ash-cath was erythematous; therefore, it was removed. The patient was started on ceftriaxone. Over the next couple of days the patient's ecchymoses over the thighs began to worsen accompanied with induration, bullae and necrosis. The lesions started spreading to the lower abdomen as well (Figures 1 and 2).

Given the typical skin lesions in a patient with DM and end-stage renal disease (ESRD) on hemodialysis, with an increased calcium phosphate product (Ca × PO_4) at 65.5 mg^2/dL^2, a diagnosis of Calcific Uremic Arteriopathy (CUA) was made. Her other risk factors included morbid obesity, history of treatment with calcium based phosphate binder Phoslo, hypoalbuminemia and hyperphosphatemia. Further coagulation studies and ANA were normal, therefore, ruling out a possibility of hypercoagulable conditions or vasculitis. Plastic surgery service performed multiple debridements of the lesions over the thighs. Biopsy of the lesions revealed chronic skin gangrene. Tissue cultures grew vancomycin resistant enterococcus (VRE) and MSSA. Appropriate antibiotic therapy was started based on these sensitivities and daily dialysis treatments continued. But despite these measures, her skin lesions continued to worsen. She eventually developed severe sepsis and septic shock with disseminated intravascular coagulation (DIC) and passed away.

Discussion
Calciphylaxis, also called Calcific Uremic Arteriopathy (CUA), is a rare but life-threatening condition characterized by vascular calcification and cutaneous necrosis usually seen in patients with ESRD on long-term dialysis. In this population, the prevalence of CUA is 4.1% [1]. It was first described in 1962 by Selye in nephrectomized rats [2]. Since 1976 this condition has been reported primarily in patients with ESRD [3]. Although its pathogenesis is unclear, hypercalcemia, hyperphosphatemia, with an elevated calcium phosphate product, and secondary hyperparathyroidism have been implicated in its pathogenesis. The Ca × PO_4 product is derived by multiplying total calcium by phosphate and should normally be less than 30 mg^2/dL^2 (22.2 – 45.5 mg^2/dL^2).

There are many risk factors associated with this condition as highlighted in Table 1[4-11]. Of these factors, some –
such as Vitamin D and PTH – are called sensitizers and others – such as trauma and iron dextran injections – are called challengers. It is the interaction of sensitizers and challengers that lead to abnormal calcium and phosphate metabolism with calcification of small and medium sized arteries and arterioles leading to occlusion of the vessel and tissue infarction.

Clinical features
Patients with calciphylaxis present with acute onset of exquisitely tender cutaneous nodules or plaques with violaceous or black discoloration. The distribution of these areas can be proximal or distal. In case of proximal distribution, the cutaneous findings appear in areas with high content of adipose tissue such as trunk, thighs and buttocks. This variant carries poor prognosis, while the distally localized disease, affecting the extremities and digits, is less severe. Rarely has the disease been found to affect the face, shoulder, genitalia and internal organs. The lesions rapidly progress and translate into necrotic non-healing ulcers and wet gangrene, which tend to get super infected. Mortality rates double when lesions ulcerate, reaching as high as 80% [4]. The leading cause of death at this point becomes sepsis and skin necrosis [8-12].

Diagnosis
Many medical conditions can masquerade CUA, especially when the disease is distally localized involving the extremities. Differential diagnoses of CUA are highlighted in Table 2. Diagnosis is usually based on a triad of findings: characteristic cutaneous features in a uremic patient with abnormal biochemistry.

Laboratory workup frequently shows hypercalcemia, hyperphosphatemia, and increased parathyroid hormone levels. To complete the workup, it is recommended to obtain coagulation studies, including prothrombin time (PT), partial thromboplastin time (PTT) and protein C and S levels to rule out hypercoagulable state. Autoimmune workup may be needed also to rule out vasculites. Imaging studies are not always helpful in diagnosis of CUA. Plain radiographs and computed tomography may show linear calcification of vessels. This finding is nonspecific and is commonly encountered in diabetes and ESRD. Xeroradiography, a high-definition x-ray photography that tends to improve structure visibility, is the best imaging to study soft tissue calcification [13]. Bone scan is positive in majority of patients with CUA and can be used to assess response to treatment. Trans-cutaneous oxygen saturation is low and may aid in the diagnosis of CUA [14]. Biopsy of skin lesion shows calcium deposition in tunica media of small and medium sized arteries and arterioles with intimal proliferation, lobular fat necrosis with infiltration of neutrophils, lymphocytes and macrophages. However biopsy is needed only in equivocal cases because of the risk of biopsy itself leading to development of non-healing ulcers.

Treatment
Early diagnosis of CUA is necessary to reduce morbidity and mortality. Management is chiefly supportive and multidisciplinary. Triggering agents such as warfarin, corticosteroids, calcium, vitamin D, parenteral iron therapy should be discontinued. If levels of calcium and phosphate and, subsequently Ca × PO₄ product are elevated, they should be normalized with dietary restriction of phosphorus through low protein diet and usage of calcium free phosphate binders such as sevelamer hydrochloride [15-17]. Increasing the frequency of dialysis, using a low calcium dialysate, is also recommended. Calcimimetics such as cinacalcet can help reduce parathyroid hormone levels, and hence calcium and phosphorus, in

---

Table 1: Risk factors for Calciphylaxis.

| Patient-related factors | Biochemical factors | Disease factors | Medication-related factors |
|------------------------|---------------------|----------------|--------------------------|
| Female sex; Caucasian race; Morbid obesity (BMI > 30 kg/m²); Protein malnutrition (serum albumin ~2 gm/dL); Recent weight loss (>10% in 6 months). | Hypercalcaemia >10.5 mg/dL; Hyperphosphataemia (>6.5 mg/dL); Calcium × Phosphate product (Ca × PO₄) > 55 mg²/dL²; Alkaline Phosphatase 10 IU above normal; Hyperparathyroidism (primary or secondary). | ESRD on replacement therapy; Diabetes Mellitus; Cirrhosis of liver; Hypercoagulable states (e.g. Protein C and S deficiency); Malignancy, Multiple myeloma, Lymphoma, Cholangiocarcinoma. | Warfarin therapy; Use of steroids; Use of vitamin D & calcium based phosphate binders; Drug infusions such as parenteral iron therapy; Trauma (e.g. subcutaneous insulin injections). |
secondary hyperparathyroidism by increasing the sensitivity of calcium sensing receptors in parathyroid gland [18]. Bisphosphonates, sodium thiosulphate and hyperbaric oxygen reduce pain and hasten healing [19-21]. Parathyroidectomy is indicated in secondary hyperparathyroidism with CUA [22]. Pain relief with large doses of analgesics and lumbar sympathetic blockade may be necessary. Serial debridement of infected necrotic tissue and broad-spectrum antibiotics aid in wound healing and treating sepsis.

**Conclusion**
Calciphylaxis is a rare but fatal disease. Hence great emphasis needs to be placed on prevention. Patients need to be educated regarding the importance of compliance with medications, dialysis, and proper diet and weight reduction. Avoiding the triggering factors and maintaining normal levels of calcium, phosphate and Ca × PO₄ product seems to be the key, although CUA can occasionally occur in the absence of renal disease and a normal Ca × PO₄ product [23-26].

**Competing interests**
The authors declare that they have no competing interests.

**Authors' contributions**
Both authors are involved in writing this case report.

**Consent section**
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**References**
1. Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on Hemodialysis: a prevalence study. *Surgery* 1997, 122:1083-90.
2. Selye H: Calciphylaxis. Chicago: University of Chicago Press; 1962.
3. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG: Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. *Arch Intern Med* 1976, 136:1273-80.
4. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. *Kidney Int* 2002, 61:2210-7.

---

**Table 2: Differential diagnosis of Calciphylaxis.**

| Disease                          | Distribution       | Chief characteristics                                                                 |
|----------------------------------|--------------------|----------------------------------------------------------------------------------------|
| Peripheral Vascular Disease      | Lower extremities  | Absent pulses, abnormal ankle brachial pressure index                                   |
| Venous ulcer                     | Above the malleoli | Reddish brown discoloration with brawny edema suggesting venous stasis                 |
| Leucocytoclastic vasculitis      | Symmetric, lower extremities | Palpable purpura evolve into hemorrhagic papules with milder symptoms; Positive serology/cryoglobulins; Characteristic skin biopsy |
| Pyoderma gangrenosum             | Lower extremities  | Associated with IBD and malignancy; Starts as a pustule, enlarges into violaceous erythematous plaque which ulcerates with heaped-up borders |
| Disseminated Intravascular Coagulation | Generalized | Widespread rapidly developing purpura. Associated with shock or disseminated infection and multi organ failure; A consumption coagulopathy |
| Warfarin-induced skin necrosis   | Extremities, breast, trunk | History of warfarin use; May have associated protein C and S deficiency; Starts as erythematous macules which become edematous and necrotic; Skin biopsy shows fibrin thrombi within the blood vessels with interstitial hemorrhage |
| Atheroembolic phenomena          | Diffuse            | Starts as purpura after vascular procedure such as angiography                         |
| Nephrogenic systemic fibrosis    | Symmetrical, extremities | Commonly associated with end stage renal disease on dialysis; May be associated with Gadolinium contrast agent; Presents as papules or plaques – areas of thick hardened skin with hyperpigmentation; Biopsy shows increased collagen bundles and fibroblast like cells |
| Hypercoagulable states e.g. Protein C & S deficiency | Trunk and extremities | History of thromboembolic events; Skin necrosis develops after initiating warfarin; Ecchymotic skin lesions coalesce and ulcerate leading to necrosis |
5. Mazhar AR, Johnson RJ, Gillen D, Stovelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with Calciphylaxis in end stage renal disease. Kidney Int 2001, 60:324-32. 

6. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL: A case control study of proximal calciphylaxis. Am J Kidney Dis 1998, 32:376-83. 

7. Ruggian J, Maesaka JK, Fishbane S: Proximal calciphylaxis in four insulin-requiring diabetic hemodialysis patients. Am J Kidney Dis 1996, 28:409-14. 

8. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from Calcemic Uremic Arteriopathy. Am J Kidney Dis 1998, 32:384-91. 

9. Perez-Mijares R, Guzman-Zamudio JL, Payan-Lopez J, Rodriguez-Fernandez A, Gomez-Fernandez P, Almaraz-Jimenez M: Calciphylaxis in a hemodialysis patient: functional protein S deficiency? Nephrol Dial Transplant 1996, 11:1856-9. 

10. Kent RB, Lyerly RT: Systemic Calciphylaxis. South Med J 1994, 87:278-81. 

11. Riegert-Johnson DL, Kaur JS, Pfeifer EA: Calciphylaxis associated with cholangiocarcinoma treated with low-molecular-weight heparin and vitamin K. Mayo Clin Proc 2001, 76:749-52. 

12. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of Renagel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998, 13:2303-10. 

13. Shiraishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita M, Tomita K: Successful treatment of a patient with severe calcific uremic arteriopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2001, 37:97-806. 

14. Russell R, Brookshire MA, Zekonis M, Moe SM: Distal calcific uremic arteriopathy in hemodialysis patient responds to lowering Ca × P product and aggressive wound care. Clin Nephrol 2002, 58:238-43. 

15. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendation for a change in management. Am J Kidney Dis 2000, 35:1226-37. 

16. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of Renagel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998, 13:2303-10. 

17. Velasco N, MacGregor MS, Innes A, Mackay IG: Successful treatment of calciphylaxis with cinacalcet- an alternative to parathyroidectomy? Nephrol Dial Transplant 2006, 21:1999-2004. 

18. Shiraiishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita M, Tomita K: Successful treatment of a patient with severe calcific uremic arteriopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2001, 37:97-806. 

19. Benedetto BJ, Emhoff TA: The use of hyperbaric oxygen for the management of calciphylaxis. Curr Surg 2000, 57:507. 

20. Meissner M, Bauer R, Beier C, Beetz C, Wolter M, Kaufmann R, Gille J: Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006, 212:373-6. 

21. Girgotto JA, Harmon JW, Ratiner LE, Nicol TL, Wong L, Chen H: Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001, 130:45-51. 

22. Barni YM, Graves GS, Knocel H: Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease. Am J Kidney Dis 1997, 29(5):773-6. 

23. Pollock B, Cunliffe WJ, Merchant WJ: Calciphylaxis in the absence of renal failure. Clin Exp Dermatol 2000, 25(5):89-92. 

24. Fader DJ, Kang S: Calciphylaxis without renal failure. Arch Dermatol 1996, 132:837-838. 

25. Weenig RH, Sewell LD, Davis MP, McCarthy James T, Pittelkow Mark R: Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007, 56(4):569-79.